Cited by 309Treatment of Major DepressionElectroconvulsive Therapy StudiesTryptophan and brain disorders

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

Open access

Ibrahim, Lobna, DiazGranados, Nancy, Franco-Chaves, Jose, Brutsche, Nancy, Henter, Ioline D, Kronstein, Phillip, Moaddel, Ruin, Wainer, Irving, Luckenbaugh, David A, Manji, Husseini K, Zarate, Carlos A·2012·Neuropsychopharmacology

DOI 10.1038/npp.2011.338PMC PMC3327857

Open this paper in CoChat — free account Open PDF

Abstract

The N-methyl-D-aspartate antagonist ketamine has rapid antidepressant effects in patients with treatment-resistant major depression (TRD); these effects have been reported to last for 1 week in some patients. However, the extent and duration of this antidepressant effect over longer periods has not been well characterized under controlled conditions. Riluzole, a glutamatergic modulator with antidepressant and synaptic plasticity-enhancing effects, could conceivably be used to promote the antidepressant effects of ketamine. This study sought to determine the extent and time course of antidepressant improvement to a single-ketamine infusion over 4 weeks, comparing the addition of riluzole vs placebo after the infusion. Forty-two subjects (18-65) with TRD and a Montgomery-Asberg Depression Rating Scale (MADRS) score of ≥ 22 received a single intravenous infusion of ketamine (0.5 mg/kg). Four to six hours post-infusion, subjects were randomized to double-blind treatment with either riluzole (100-200 mg/day; n=21) or placebo (n=21) for 4 weeks. Depressive symptoms were rated daily. A significant improvement (P<0.001) in MADRS scores from baseline was found. The effect size of improvement with ketamine was initially large and remained moderate throughout the 28-day trial. Overall, 27% of ketamine responders had not relapsed by 4 weeks following a single ketamine infusion. The average time to relapse was 13.2 days (SE=2.2). However, the difference between the riluzole and placebo treatment groups was not significant, suggesting that the combination of riluzole with ketamine treatment did not significantly alter the course of antidepressant response to ketamine alone.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/npp.2011.338

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citation
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,860

Show all 32 references

Research works printed but not linked: 2

Aitken RC (1969). Measurement of feelings using visual analogue scales. Proc R Soc Med 62: 989–993.
First MB, Spitzer RL, Gibbon M, Williams AR (2001). Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York State Psychiatric Institute, Biometrics Research: New York.

Sorted by citations

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citation
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citation
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Self-citation
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 663
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study.
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Self-citation
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
Ketamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
Self-citation
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Self-citation
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
Family and Academic Stress and Their Impact on Students' Depression Level and Academic Performance
Deng, Y., Cherian, J., Khan, N. U. N., Kumari, K., Sial, M. S., Comite, U., Gavurova, B., & Popp, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.869337 · Cited by 371
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Self-citation
Ketamine use in current clinical practice
Gao, M., Rejaei, D., & Liu, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.5 · Cited by 286
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283
Self-citation
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Self-citation
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.105 · Cited by 271
Self-citation
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder
Duncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256
Self-citation
From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders
Sanacora, G., & Banasr, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.032 · Cited by 239
Ketamine for Treatment-Resistant Unipolar Depression
Mathew, S. J., Shah, A. A., Lapidus, K. A. B., Clark, C. T., Jarun, N., Ostermeyer, B. K., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 245
The role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V. N., Cristancho, P., Miller, J. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.016 · Cited by 230
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Niciu, M. J., Roiser, J. P., & Zarate, C. A. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568041 · Cited by 224
Self-citation
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression
Shiroma, P. R., Johns, B., Kuskowski, M. A., Wels, J., THURAS, P. D., Albott, C. S., & Lim, K. O. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.036 · Cited by 222
Targeting the Glutamatergic System to Treat Major Depressive Disorder: Rationale and Progress to Date
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Self-citation
Serial infusions of low-dose ketamine for major depression
Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., Ritter, M. J., Schak, K. M., Sola, C. L., Hanson, A. J., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478283 · Cited by 221
Pharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 228
Mechanism of action of ketamine
Stahl, S. M. (2013) · CNS Spectrums · doi:10.1017/s109285291300045x · Cited by 218
Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients
Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213
Self-citation
Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: A systematic review and meta-analysis
Godfrey, K. E. M., Gardner, A. C., Kwon, S., Chea, W., & Muthukumaraswamy, S. D. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.015 · Cited by 218
Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials
Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: A perspective review
Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Self-citation
Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression
Cornwell, B. R., Salvadore, G., Furey, M., Marquardt, C. A., Brutsché, N. E., Grillon, C., & Zarate, C. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.029 · Cited by 205
Self-citation
Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition
Miller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action
Naughton, M., Clarke, G. A., O’Leary, O. F., Cryan, J. F., & Dinan, T. G. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 195
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
McIntyre, R. S., Carvalho, I. P., Lui, L. M. W., Majeed, A., Masand, P. S., Gill, H., Rodrigues, N. B., Lipsitz, O., Coles, A. C., Lee, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.050 · Cited by 187
Fast-acting antidepressant activity of ketamine: Highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Ketamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration
Evans, J. W., Szczepanik, J., Brutsché, N., Park, L. T., Nugent, A. C., & Zarate, C. A. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.027 · Cited by 173
Self-citation
The Action of Antidepressants on the Glutamate System: Regulation of Glutamate Release and Glutamate Receptors
Musazzi, L., Treccani, G., Mallei, A., & Popoli, M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.009 · Cited by 178
Kynurenine pathway metabolites and suicidality
Bryleva, E. Y., & Brundin, L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.034 · Cited by 168
Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study
Carlson, P. J., Diazgranados, N., Nugent, A. C., Ibrahim, L., Luckenbaugh, D. A., Brutsche, N., Herscovitch, P., Manji, H. K., Zarate, C. A., & Drevets, W. C. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.008 · Cited by 168
Self-citation
Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trial
Irwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Self-citation
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Self-citation
Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery
Remus, J. L., & Dantzer, R. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw028 · Cited by 170
Effects of Striatal ΔFosB Overexpression and Ketamine on Social Defeat Stress–Induced Anhedonia in Mice
Donahue, R. J., Muschamp, J. W., Russo, S. J., Nestler, E. J., & Carlezon, W. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.014 · Cited by 161
“clinical studies reporting that patients who respond to acute ketamine often experience relapse within several days (31,39,80) as well as preclinical reports of acute but not persistent antidepressant-like effects of ketamine in the forced swim test”
Background
Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds
Niciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 166
Self-citation
Clinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2011) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 164
Legal highs: staying on top of the flood of novel psychoactive substances
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314559539 · Cited by 162
Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats
Koike, H., & Chaki, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.065 · Cited by 157
New targets for rapid antidepressant action
Machado‐Vieira, R., Henter, I. D., & Zarate, C. A. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 161
Self-citation
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 163
Self-citation
Role of calcium, glutamate and NMDA in major depression and therapeutic application
Deutschenbaur, L., Beck, J., Kiyhankhadiv, A., Mühlhauser, M., Borgwardt, S., Walter, M., Hasler, G., Sollberger, D., & Lang, U. E. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.02.015 · Cited by 158
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Self-citation
Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study
Hu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291715002159 · Cited by 146
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials
Ballard, E. D., Wills, K. E., Lally, N., Richards, E. M., Luckenbaugh, D. A., Walls, T. L., Ameli, R., Niciu, M. J., Brutsché, N. E., Park, L., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.057 · Cited by 155
Self-citation
Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression
Lara, D. R., Bisol, L. W., & Munari, L. R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 140
Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 145
Overview of Glutamatergic Dysregulation in Central Pathologies
Miladinovic, T., Nashed, M. G., & Singh, G. (2015) · Biomolecules · doi:10.3390/biom5043112 · Cited by 145
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
Niciu, M. J., Shovestul, B. J., Jaso, B. A., Farmer, C., Luckenbaugh, D. A., Brutsché, N. E., Park, L. T., Ballard, E. D., & Zarate, C. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.049 · Cited by 137
Self-citation
Longitudinal Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal Cortex
Phoumthipphavong, V., Barthas, F., Hassett, S., & Kwan, A. C. (2016) · eneuro · doi:10.1523/eneuro.0133-15.2016 · Cited by 132
Activation of Mammalian Target of Rapamycin and Synaptogenesis: Role in the Actions of Rapid-Acting Antidepressants
Dwyer, J. M., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.011 · Cited by 139
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
Self-citation
Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Ketamine as a new treatment for depression: A review of its efficacy and adverse effects
Katalinic, N., Lai, R., Somogyi, A. A., Mitchell, P. B., Glue, P., & Loo, C. K. A. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413486842 · Cited by 132
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Lucido, M. J., Bekhbat, M., Goldsmith, D. R., Treadway, M. T., Haroon, E., Felger, J. C., & Miller, A. H. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000043 · Cited by 133
The role of NMDA receptors in the pathophysiology and treatment of mood disorders
Ghasemi, M., Phillips, C., Trillo, L., Miguel, Z. D., Das, D., & Salehi, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.017 · Cited by 132
Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis
Lee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
Bobo, W. V., Voort, J. L. V., Croarkin, P. E., Leung, J. G., Tye, S. J., & Frye, M. A. (2016) · Depression and Anxiety · doi:10.1002/da.22505 · Cited by 123
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression
Wilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L. R., Griepp, M., Ostroff, R. B., & Sanacora, G. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000457960 · Cited by 122
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 126
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 121
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113
Self-citation
Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation
Cusin, C., Ionescu, D. F., Pavone, K. J., Akeju, O., Cassano, P., Taylor, N. E., Eikermann, M., Durham, K. E., Swee, M. B., Chang, T. E., et al. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416631828 · Cited by 114
Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response
Murrough, J. W., Wan, L.-B., Iacoviello, B. M., Collins, K. A., SOLON, C. A., Glicksberg, B. S., Perez, A. M., Mathew, S. J., Charney, D. S., Iosifescu, D. V., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3255-x · Cited by 113
Classics in Chemical Neuroscience: Ketamine
Tyler, M. W., Yourish, H. B., Ionescu, D. F., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00074 · Cited by 108
Sleep Architecture Parameters as a Putative Biomarker of Suicidal Ideation in Treatment-Resistant Depression
Bernert, R., Luckenbaugh, D., Duncan, W., Iwata, N. G., Ballard, E., & Zarate, C. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.08.050 · Cited by 76
Self-citation
A Word to the Wise About Ketamine
Schatzberg, A. F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101434 · Cited by 102
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Jaso, B. A., Niciu, M. J., Iadarola, N. D., Lally, N., Richards, E. M., Park, M., Ballard, E. D., Nugent, A. C., Machado‐Vieira, R., & Zarate, C. A. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160321123221 · Cited by 101
Self-citation
Randomized trial of ketamine masked by surgical anesthesia in patients with depression
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., & Heifets, B. D. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00140-x · Cited by 131
The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97
Ketamine: differential neurophysiological dynamics in functional networks in the rat brain
Ahnaou, A., Huysmans, H., Biermans, R., Manyakov, N. V., & Drinkenburg, W. H. I. M. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.198 · Cited by 97
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder
Dean, R. L., Hurducas, C., Hawton, K., Spyridi, S., Cowen, P. J., Hollingsworth, S., Marquardt, T., Barnes, A., Smith, R., McShane, R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub3 · Cited by 95
Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression
Park, M., Newman, L. E., Gold, P. W., Luckenbaugh, D. A., Yuan, P., Machado-Vieira, R., & Zarate, C. A. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.025 · Cited by 93
Self-citation
Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine’s Rapid Antidepressant Properties
Duncan, W. C., Slonena, E., Hejazi, N. S., Brutsche, N., Yu, K. C., Park, L., Ballard, E. D., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.011 · Cited by 93
Self-citation
Neuroplasticity and the next wave of antidepressant strategies
Hayley, S., & Litteljohn, D. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00218 · Cited by 92
Novel glutamatergic drugs for the treatment of mood disorders
Murrough, J. W., Lapidus, K. A. B., & Soleimani, L. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36689 · Cited by 96
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience
Tundo, A., de Filippis, R., & Proietti, L. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.330 · Cited by 94
The promise of ketamine for treatment‐resistant depression: current evidence and future directions
DeWilde, K. E., Levitch, C. F., Murrough, J. W., Mathew, S. J., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12646 · Cited by 95

Authors: Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A.
Affiliations: National Institutes of Health (US)
Corresponding author: Zarate, Carlos A
ORCID: DiazGranados, Nancy
Henter, Ioline D
Moaddel, Ruin
Wainer, Irving
Manji, Husseini K
Zarate, Carlos A
Venue: Neuropsychopharmacology
Publisher: Springer Science and Business Media LLC
Published: 2012-02-01
Volume: 37
Issue: 6
Pages: 1526-1533
ISSN: 0893-133X (ISSN-L)
1740-634X
DOI: 10.1038/npp.2011.338
PMC: PMC3327857
OpenAlex: W2006861654
Cited by: 309
References: 32
Citations by year: 2026: 8 · 2025: 8 · 2024: 13 · 2023: 17 · 2022: 19 · 2021: 16 · 2020: 18 · 2019: 19 · 2018: 19 · 2017: 17 · 2016: 38 · 2015: 37 · 2014: 33 · 2013: 30 · 2012: 14
FWCI: 26.82
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Neuropsychopharmacology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: ketamine, riluzole, treatment-resistant depression, major depressive disorder, relapse, NMDA receptor antagonists, glutamatergic modulation, combination therapy
MeSH terms: Adolescent, Adult, Aged, Depression, Double-Blind Method, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Time Factors, Outcome Assessment, Health Care, Excitatory Amino Acid Antagonists, Riluzole, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks